{"id":548330,"date":"2021-06-18T19:18:01","date_gmt":"2021-06-18T19:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=548330"},"modified":"2021-06-18T19:18:01","modified_gmt":"2021-06-18T19:18:01","slug":"cold-agglutinin-disease-market-insights-and-market-forecast-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cold-agglutinin-disease-market-insights-and-market-forecast-by-delveinsight_548330.html","title":{"rendered":"Cold Agglutinin Disease Market Insights and Market Forecast by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1624008010.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cold Agglutinin Disease Market Insights and Market Forecast by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1624008010.png\" alt=\"Cold Agglutinin Disease Market Insights and Market Forecast by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>&ldquo;<span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cold-agglutinin-disease-cad-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Cold Agglutinin Disease Market<\/a><\/span><\/strong>&rdquo; report has been added to DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Cold agglutinin disease (CAD) is an uncommon autoimmune hemolytic anemia in which a well-defined, clonal low-grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. It is mediated by cold agglutinins (CA), without any underlying disease such as aggressive lymphoma, other overt malignancies, or specific infections.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cold-agglutinin-disease-cad-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Cold Agglutinin Disease Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;Cold Agglutinin Disease (CAD) &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cold-agglutinin-disease-cad-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Cold Agglutinin Disease Market<\/a><\/span>: Report<\/strong><\/p>\n<p style=\"text-align: justify;\">The Cold Agglutinin Disease (CAD) market report provides current treatment practices, emerging drugs, Cold Agglutinin Disease (CAD) market share of the individual therapies, current and forecasted Cold Agglutinin Disease (CAD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Cold Agglutinin Disease (CAD) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request free sample copy- <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cold-agglutinin-disease-cad-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/cold-agglutinin-disease-cad-market <\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Market: Regions Covered<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The United States<\/li>\n<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)<\/li>\n<li>Japan<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cold-agglutinin-disease-cad-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Cold Agglutinin Disease Market<\/a><\/span>: Key Players<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Sanofi<\/li>\n<li>Apellis Pharmaceuticals<\/li>\n<li>Janssen Pharmaceutical<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Market: Drugs<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Sutimlimab<\/li>\n<li>APL-2<\/li>\n<li>Bortezomib<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Market: Size<\/strong><\/p>\n<p style=\"text-align: justify;\">The key driver for the surge in market size is the rise in number of prevalent cases. Further launch of potential therapies may increase the market size in coming years, assisted by an increase in diagnosed prevalent population of CAD in the 7MM.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Market: Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">The current therapeutic market of CAD is dominated by non-pharmacological (cold avoidance) and pharmacological management. Corticosteroids, Alkylating agents, Purine nucleoside analogs and majorly Biologics, such as Rituximab monotherapy or combination therapy (Fludarabine and Rituximab, Bendamustine and Rituximab) and others are the major therapeutic line of treatment for CAD. Folic acid supplements are advisable to meet the demand for increased red blood cell production in the bone marrow. Other treatment options, such as Transfusion are also used.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Market: Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\">The treatment scenario in the United States and Europe is similar to Japan. There are no approved therapies available for the treatment of cold agglutinin disease and current treatment landscape is filled with the evidence-based treatment. The CAD market is filled with the paucity of the disease understanding, limited epidemiological studies, and limited therapeutic options.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Market: Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">The therapeutic market is driven by the increase in prevalent cases and is mainly driven by the patient pools of elderly age groups. The current research on molecular level details and new therapeutic targets, owing to a greater number of drugs receiving special designations by regulatory bodies and approval of the long-awaited medication, enhance hopes for the future market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Cold Agglutinin Disease (CAD)<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Cold Agglutinin Disease (CAD)<\/p>\n<p style=\"text-align: justify;\">4. Cold Agglutinin Disease (CAD): Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Cold Agglutinin Disease (CAD): Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Cold Agglutinin Disease (CAD) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Cold Agglutinin Disease (CAD) Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Cold Agglutinin Disease (CAD): Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Cold Agglutinin Disease (CAD)<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23<strong>. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cold Agglutinin Disease Market<\/strong>: <strong>Report Scope<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Cold Agglutinin Disease (CAD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Cold Agglutinin Disease (CAD) epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Cold Agglutinin Disease (CAD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Cold Agglutinin Disease (CAD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cold Agglutinin Disease (CAD) market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Why should you buy this report?<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease market<\/li>\n<li>To understand the future market competition in the Cold Agglutinin Disease (CAD) market and Insightful review of the key market drivers and barriers<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease (CAD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan<\/li>\n<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease (CAD) market<\/li>\n<li>To understand the future market competition in the Cold Agglutinin Disease (CAD) market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cold-agglutinin-disease-market-insights-and-market-forecast-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cold-agglutinin-disease-market-insights-and-market-forecast-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&ldquo;Cold Agglutinin Disease Market&rdquo; report has been added to DelveInsight &nbsp; Cold Agglutinin Disease Overview Cold agglutinin disease (CAD) is an uncommon autoimmune hemolytic anemia in which a well-defined, clonal low-grade lymphoproliferative disorder of the bone marrow results in erythrocyte &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cold-agglutinin-disease-market-insights-and-market-forecast-by-delveinsight_548330.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,413],"tags":[],"class_list":["post-548330","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/548330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=548330"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/548330\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=548330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=548330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=548330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}